NVCT News

Nuvectis Pharma to Participate at the H.C. Wainwright 27th Annual Global Investment Conference

NVCT

(NASDAQ:NVCT) Fort Lee, NJ, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that senior management will participate in the upcoming H.C. Wainwright Global Investment Conference. A Nuvectis corporate presentation delivered by Ron Bentsur, Chairman and Chief Executive Officer, will be available for on-demand viewing by conference attendees starting on Friday, September 5, 2025, at 7:00 a.m. ET. The Company will also attend virtual one-on-one meetings during the conference taking place September 8-10, 2025.

September 4, 2025Conference
Read more →

HC Wainwright & Co. Reiterates Buy on Nuvectis Pharma, Raises Price Target to $15

NVCT

April 30, 2025
Read more →

Nuvectis Pharma Unveils Poster Presentation Highlights For NXP900 From The 2025 American Association For Cancer Research Meeting Including Phase 1a Dose-Escalation Update For Treatment With NXP900

NVCT

April 29, 2025
Read more →

Maxim Group Initiates Coverage On Nuvectis Pharma with Buy Rating, Announces Price Target of $17

NVCT

April 2, 2025
Read more →

Laidlaw & Co. Initiates Coverage On Nuvectis Pharma with Buy Rating, Announces Price Target of $19

NVCT

March 17, 2025
Read more →

HC Wainwright & Co. Maintains Buy on Nuvectis Pharma, Lowers Price Target to $11

NVCT

February 25, 2025
Read more →

Nuvectis Pharma CEO Says Increased Dose Intensity Needed To Drive More Efficacy From Ovarian Cancer Lead Drug

NVCT

Nuvectis Pharma reports mixed Phase 1b results for NXP800 in ovarian cancer, showing antitumor activity and improved safety with adjusted dosing.

November 14, 2024
Read more →

Nuvectis Pharma Reports Data From Phase 1b Study Evaluating NXP800 In Patients With Platinum Resistant ARID1a-mutated Ovarian Cancer; Says Encouraged By Early Results

NVCT

November 14, 2024
Read more →

Nuvectis Pharma Q3 2024 GAAP EPS $(0.24) Beats $(0.26) Estimate, Cash, Cash Equivalents, And Short-term Investments Were $17.2M

NVCT

November 5, 2024
Read more →

Nuvectis Pharma Announces Data for NXP800 In A Preclinical Model Of ARID1a-Mutated Gastric Carcinoma

NVCT

September 13, 2022
Read more →